Investors Helping Investors Beat the Market
Results 1 - 10 of 2731 : 1 2 3 4 5 6 7 8 9 Next
Have J&J's Approval Hopes Vanished?
Johnson & Johnson might have trouble sidestepping the competition.
The Meaningless Drug Approval That Could Cost the Industry Billions
Being able to use surrogate endpoints is important for drug developers.
That's what phase 2 trials are for.
Too Little, Too Late for Achillion?
Achillion produces solid hepatitis C data, but competitors are out in front.
Will the Dow Break Its Losing Streak?
A brief look at the market's moves so far today.
5 Pharmaceutical Stocks With Significant Exposure to Europe
A fracture of the European monetary union could spell trouble for these five pharmaceutical stocks.
Drug Fails: At Least It's Approved Already
Pfizer's Torisel fails to best Nexavar in a head-to-head trial.
The Dow Couldn't Hold Back These 4 Stocks
These Dow stocks bucked a down market.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK